NCT05174806 is a Phase 2 clinical trial of Topical Pravibismane in Diabetic Foot Infection, sponsored by Microbion Corporation.

Who is sponsoring NCT05174806?

NCT05174806 is sponsored by Microbion Corporation.

What drugs are being tested in NCT05174806?

Interventions in NCT05174806: Topical Pravibismane, Standard of Care.

What condition does NCT05174806 study?

NCT05174806 studies Diabetic Foot Infection, Diabetic Foot.

Is NCT05174806 still recruiting?

NCT05174806 is currently completed. Last updated 4 November 2024.

Last reviewed 2024-11-04 · How we verify

NCT05174806

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients

Completed Phase 2 Last updated 4 November 2024

What this trial tests

Phase 2 trial testing Topical Pravibismane in Diabetic Foot Infection in 47 participants. Completed in 19 January 2024.

Timeline

13 June 2022

Primary endpoint
19 January 2024

19 January 2024

Quick facts

Lead sponsor	Microbion Corporation
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	47
Start date	13 June 2022
Primary completion	19 January 2024
Estimated completion	19 January 2024
Sites	7 locations across United States

Drugs / interventions tested

Topical Pravibismane — full drug profile →
Standard of Care

Conditions studied

Diabetic Foot Infection — all drugs for Diabetic Foot Infection →
Diabetic Foot — all drugs for Diabetic Foot →

Sponsor

Microbion Corporation — full company profile →

Who can join

Adults 18 to 79, any sex, with Diabetic Foot Infection or Diabetic Foot. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, open label, controlled, multi-center study to assess safety, tolerability, and efficacy of adjunctive treatment with topically applied pravibismane (MBN-101) in patients with moderate diabetic foot infections. Patients will be randomized in a 2:1 ratio (MBN-101:standard of care). Topical pravibismane (MBN-101) will be applied three times per week for up to 12 weeks. All patients will receive systemic antibiotic treatment for a least a portion of that period. Randomization will be stratified by site.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Antibiotics in the clinical pipeline as of December 2022.
Butler MS, Henderson IR, Capon RJ, Blaskovich MAT. · · 2023 · cited 147× · PMID 37291465 · DOI 10.1038/s41429-023-00629-8
Antibacterials with Novel Chemical Scaffolds in Clinical Development.
Heimann D, Kohnhäuser D, Kohnhäuser AJ, Brönstrup M. · · 2025 · cited 10× · PMID 39847315 · DOI 10.1007/s40265-024-02137-x
Staph wars: the antibiotic pipeline strikes back.
Douglas EJA, Laabei M. · · 2023 · cited 10× · PMID 37656158 · DOI 10.1099/mic.0.001387
Diabetes and its complications: molecular mechanisms, prevention and treatment.
Zhao L, Yuan J, Yang Q, Ma J, et al · · 2026 · cited 2× · PMID 41549124 · DOI 10.1038/s41392-025-02401-w

Verify or expand the search:

Other recruiting trials for Diabetic Foot Infection

Currently open trials in the same condition.

NCT07338773 — Intraosseous vs. Intravenous Vancomycin Prophylaxis for Diabetic Foot Amputations: A Randomized Trial · Phase 4 · recruiting
NCT06667752 — Randomized Double-Blind Trial on Safety and Efficacy of Nanordica Advanced Antibacterial Wound Dressing for Diabetic Foo · NA · recruiting
NCT07040488 — Study of Infrared Thermography in Diabetic Foot in Guadeloupe · recruiting
NCT06526884 — Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC) · NA · active not recruiting
NCT05172089 — Diabetic Foot Ulcer (DFU) Biofilm Infection and Recurrence · recruiting

Other Microbion Corporation trials

Trials by the same sponsor.

NCT02723539 — A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI · Phase 1 · completed
NCT02436876 — Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05174806 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Microbion Corporation
Last refreshed: 4 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05174806.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing